researchers will employ serial magnetic resonance imaging (MRI); positron emission tomography (PET) scans; measurement of various biological compounds in blood, cerebrospinal fluid, and urine; and clinical and neuropsychological assessments to track MCI and early AD progression.
Liu et al., "A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI
cohort," NeuroImage, vol.
Lemieux, et al., "Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI
," Hippocampus, vol.
All subjects underwent a neuropsychological assessment, starting from the screening visit (visit at time = 0 ofthe ADNI
protocol) up to the baseline (visit at time = 1 month from the screening in the ADNI
protocol) and following visits.
We use the ADNI
pipeline as introduced in Jack et al.
dataset consists of more than 6000 subjects aged from 18 to 96.
Our general objective is to assess the accuracy of our automated high-dimensional morphometry technique to the hypothetical prediction of future clinical status from MRI when examining previously acquired data in a cohort of MCI subjects from the large, multicentric ADNI
dataset, compared to the currently known clinical status for these subjects, under various conditions.
The investigators used observational data from ADNI
to show that out of 675 measurements made at time points of 0, 6, 12, and 24 months, data from ADAS-Cog total scores spanned the entire range of the scale and had no floor or ceiling effects that would reduce its ability to measure changes and differences in lower-functioning or higher-functioning patients, respectively.
The datasets consists of T2-weighted MR brain images in axial plane and 256 x 256 in-plane resolution, which were downloaded from the website of Harvard Medical School (URL: http://med.harvard.edu/AANLIB/), OASIS dataset (URL: http:// www.oasis-brains.org/), and ADNI
dataset (URL: http://adni.loni.ucla.edu/).
A decline on the Functional Assessment Questionnaire and the Trail Making Test, part B, was significantly more accurate in predicting 12-month conversion than were any of the biomarkers assessed in a subanalysis of the Alzheimer's Disease Neuroimaging Initiative (ADNI
), according to Jesus Gomar, Ph.D., and his colleagues.
In a new report, researchers from the Alzheimer's Disease Neuroimaging Initiative (ADNI
) not only confirmed that certain changes in biomarker levels in cerebrospinal fluid may signal the onset of mild Alzheimer's, but also established a method and standard of testing for these biomarkers.